---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-142947"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:29:16.815956+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics amends CEO and executive severance, equity acceleration provisions

## Summary
- CEO Craig Collard's amended agreement: severance of 1x base salary + bonus (non-CIC) or 2x (CIC), plus equity acceleration.
- For performance-based equity granted after April 3, 2026, vesting accelerates at greater of actual performance or target upon qualifying termination.
- Similar amendments for CFO Duarte, CDO Forbes, COO Hensley: 12 months pay & equity (non-CIC) or 24 months & full acceleration (CIC).
- Agreements add 24-month non-competition and non-solicitation covenants; governing law changed to North Carolina.

## SEC filing metadata
- accession: 0001193125-26-142947
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526142947/0001193125-26-142947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526142947/hrtx-20260403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-142947
- JSON: https://secwatch.observer/filing/0001193125-26-142947.json
- Plain text: https://secwatch.observer/filing/0001193125-26-142947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.